Physiologically based pharmacokenitic - PBPK

Physiologically based Pharmacokinetic

For a better translation from non-clinical to human studies

Physiologically Based PharmacoKinetic (PBPK) is a mechanistic approach to predict the absorption, distribution, metabolism and excretion of drugs on the basis of:

  1. Anatomy and physiology of human or animal body
  2. Physicochemical properties of the drug
  3. In vitro data on biotransformation
  4. Transport of the drug

Connecting all these information in one model, is possible with PBPK analysis, to help you better understand the behavior of your compound and its preclinical and clinical development.

Your company has already data from preclinical studies; your drug candidate has been tested on animals; you have investigated metabolism and transporter in in vitro experimentations: these results allow to go further and start a phase I study on humans.

The PBPK study approach allows, to test in silico different dosing treatment that will be evaluated in first-in-human studies (FIH).

In addition, by avoiding unnecessary trials on healthy volunteers, PBPK can also be considered as the most adapted tool to:
  • Evaluate the likely magnitude of a drug-drug interaction
  • Determine PK in specific population (Pediatric, Hepatic or Renal Impairment)
  • Support the clinical development of a new formulation or a food effect.

PhinC Development pioneered the use of GastroPlus® software. For many years, we enhanced our expertise and established a strong partnership with SimulationsPlus® to promote best use of PBPK modeling in drug development.

Club Phase 1
GMP - Groupe de Métabolisme et Pharmacocinétique
EUFEMED
AFSSI